Developing as a significant advance in the battle against obesity, the drug is capturing considerable buzz. It combines properties of two recognized GLP-1 binding agonists, liraglutide, and an new glucose-dependent incretin component. Initial clinical results have indicated substantial fat reduction in individuals with obesity , perhaps offering a